Alaunos Therapeutics, Inc. (TCRT): Nasdaq/NYSE listing notice — Alaunos Therapeutics receives Nasdaq delisting notice for equity shortfall; 45 days to submit plan

Alaunos Therapeutics, Inc.

Nasdaq notified Alaunos on April 9, 2026, of non-compliance with minimum $2.5M stockholders' equity; 2025 10-K reported $2.153M.
Company also fails alternative listing standards: market value of listed securities $35M or net income $500K last fiscal year.
Must submit compliance plan by May 26, 2026; if accepted, Nasdaq may grant up to 180-day extension.
If plan rejected or extension not achieved, Company may request hearing before Nasdaq hearings panel.
Trading in TCRT common stock continues pending disclosure and compliance process.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, reported stockholders’ equity of $2,153,000. As of the date of the Notice

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-157126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.